SWOG Institutional Grant

描述(由申请人提供)： H.Lee Moffitt癌症中心和研究所(HLMCC)由佛罗里达州立法机构于1981年成立，致力于癌症的预防和治疗。它位于佛罗里达州中西部，是将新的科学发现转化为最先进的临床试验的理想地点。与佛罗里达州罕见的人口增长相称，HLMCC目前在门诊癌症患者就诊数量上排名全国第三。它是佛罗里达州唯一一家由国家癌症研究所指定的单一地点的综合性癌症中心，它于2001年获得这一认可，除了波多黎各和中南美洲外，它还接受来自美国东南部整个地区的患者转介。2005年，HLMCC调查人员以压倒性多数决定将合作小组的参与从东部合作小组转移到西南肿瘤小组(SWOG)：这一决定是基于地理位置和对SWOG临床研究活动具有丰富经验的调查人员的招募。作为这些中心提供全面癌症护理的使命的一部分，除了波多黎各，莫菲特还在佛罗里达州和佐治亚州建立了广泛的附属网络，涉及12个机构和200多名有资质的调查人员。这个附属网络将是SWOG试验应计费用的一个组成部分，莫菲特SWOG办公室将与HLMCC附属办公室密切合作，指导对工作人员的持续认证、监测和教育。在HLMCC的每个与疾病相关的肿瘤项目中都确定了主要的研究人员，他们在设计和编写由研究人员发起的临床试验方面具有经验，其中许多人获得了NCI的拨款：这些调查人员将在HLMCC及其附属网络中领导和及时激活和积累SWOG试验，此外还将积极参与一年两次的SWOG会议。因此，通过积极参与SWOG合作试验的积极设计和积累，我们相信HLMCC将推进其为美国东南部提供全面癌症护理的目标，并继续履行其宣称的治疗和预防癌症这一致病和死亡原因的使命。

DESCRIPTION (provided by applicant): The H. Lee Moffitt Cancer Center and Research Institute (HLMCC), founded by the Florida State legislature in 1981, is dedicated to the prevention and cure of cancer. Situated in West Central Florida, it is ideally situated to translate novel scientific discoveries into state-of-the-science clinical trials. Commensurate with the unprecidented population growth in the state of Florida, the HLMCC presently ranks third in the country in numbers of ambulatory cancer patient visits. It is the only single-site National Cancer Institute-designated comprehensive cancer center in the state of Florida, a recognition it received in 2001 and receives patient referrals from entire Southeast of the United States, in addition to Puerto Rico and Central and South America. In 2005 the HLMCC investigators overwhelmingly decided to transfer co-operative group participation, from the Eastern Cooperative Group to the Southwest Oncology Group (SWOG): this decision was based on geography, and the recruitment of investigators with deep experience in SWOG clinical research activity. As part of the centers' mission to provide total cancer care, Moffitt has developed an extensive affiliate network throughout the states of Florida and Georgia, in addition to the island of Puerto Rico involving twelve institution and over 200 credentialed investigators. This affiliate network will be an integral part of accrual to SWOG trials, and the Moffitt SWOG office will work closely with the HLMCC affiliate office to guide the ongoing credentially, monitoring and education of staff. Key investigators have been identified in each of the disease related tumor programs at the HLMCC, with experience in the design, and writing of investigator-initiated clinical trials, many of whom have NCI grant funding: these investigators will provide the leadership and of the timely activation and accrual of SWOG trials within HLMCC and throughout its' affiliate network, in addition to providing active participation in the biannual SWOG meetings. Thus, through robust participation in the active design and accrual to SWOG cooperative trials, we believe that the HLMCC will advance its goal of providing total cancer care to the Southeast United States, and continue to pursue its' stated mission of curing and preventing cancer as a cause of illness and death.